#United States #Nashville #DAXXIFY #Blue Lizard #Revance

Revance Transitions Leadership for Future Growth

Revance Therapeutics, a rapidly expanding leader in both aesthetics and skincare, has announced a significant leadership transition intended to foster the company’s next phase of growth and innovation. The founder and current CEO, Jeff Bedard, is stepping into the role of Executive Chairman of the Board, while Nadeem Moiz, who currently serves as President, Chief Operating Officer, and Chief Financial Officer, will take on the position of Chief Executive Officer starting October 1, 2025.

This strategic leadership shift aims to ensure that Revance continues its trajectory as a recognized trailblazer in the skincare industry, marked by a commitment to scientific rigor and dedication to customer-centric solutions. The transition comes during a transformative period for the company, particularly following its acquisition by Crown Laboratories earlier this year, which has broadened its capabilities and offerings.

In a joint statement, Co-Founders and Managing Partners Andrew Goldman and David Solomon emphasized the significance of this transition, expressing their gratitude for Bedard’s extraordinary vision and leadership, which has established the current trajectory and entrepreneurial culture at Revance. "This thoughtfully planned transition acknowledges the outstanding company that Jeff has built," they remarked.

The newly proclaimed Executive Chairman, Bedard, will continue to play an integral role in the company’s strategic direction while guiding Moiz and the rest of the leadership team. His continued involvement is expected to facilitate a seamless transition in Revance’s operational and customer-focused initiatives, ensuring alignment with the company’s growth plans.

Nadeem Moiz, who joined Revance in 2022, has been integral to the company’s recent advancements and the scaling of its business model. His extensive background in operational leadership and strategic management positions him as an optimal choice to steer the company's future endeavors. Moiz expressed enthusiasm for his new role, stating, "I am energized about the future of Revance and appreciative of the trust placed in me by Jeff and the Board to guide the company forward."

Revance’s evolution comes at a crucial time when the demand for innovative skincare and aesthetic solutions is on the rise. Earlier in the year, the company united its offerings under the Revance brand, integrating various award-winning consumer brands, including PanOxyl®, Blue Lizard®, and StriVectin®, alongside innovative aesthetic treatments such as DAXXIFY® and the RHA® Collection by Teoxane SA.

Bedard, reflecting on the company's journey, stated, "I founded the company 25 years ago with a vision to develop a unique portfolio of safe and effective scientific solutions for lifelong healthy skin. I am thrilled to transition into the role of Executive Chairman, allowing Nadeem to lead as CEO."

As the landscape of skincare continues to evolve, Revance’s robust portfolio—which includes aesthetic injectables and advanced skincare products—positions it well in the competitive market. The leadership transition is not only a testament to the company’s growth but also paves the way for future innovations and collaborations that align with industry demands.

In summary, Revance's leadership transition marks a pivotal moment in its journey as a prominent player in aesthetics and skincare. With Bedard continuing as Executive Chairman and Moiz stepping into the CEO role, the future looks promising for the company as it continues to innovate and adapt in a rapidly changing industry.